135 related articles for article (PubMed ID: 35121930)
1. KRAS inhibitors, approved.
Rosell R; Aguilar A; Pedraz C; Chaib I
Nat Cancer; 2021 Dec; 2(12):1254-1256. PubMed ID: 35121930
[No Abstract] [Full Text] [Related]
2. Investigational KRAS Inhibitor Tested for Advanced Solid Tumors.
Abbasi J
JAMA; 2020 Nov; 324(18):1818. PubMed ID: 33170223
[No Abstract] [Full Text] [Related]
3. Dueling KRAS
Cancer Discov; 2020 Jan; 10(1):10. PubMed ID: 31822538
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Resistance to KRAS
Akhave NS; Biter AB; Hong DS
Cancer Discov; 2021 Jun; 11(6):1345-1352. PubMed ID: 33820777
[No Abstract] [Full Text] [Related]
5. IASLC 2019 World Conference on Lung Cancer.
Venkatesan P
Lancet Respir Med; 2019 Nov; 7(11):930-932. PubMed ID: 31548107
[No Abstract] [Full Text] [Related]
6. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
7. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
8. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for non-small cell lung cancer.
Toloza EM; D'Amico TA
Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
[TBL] [Abstract][Full Text] [Related]
10. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
11. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
12. Targeting the KRAS G12C mutation in patients with advanced solid tumors.
Hong DS
Clin Adv Hematol Oncol; 2019 Nov; 17(11):612-614. PubMed ID: 31851163
[No Abstract] [Full Text] [Related]
13. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough in targeted therapy for non-small cell lung cancer.
Ye Z; Huang Y; Ke J; Zhu X; Leng S; Luo H
Biomed Pharmacother; 2021 Jan; 133():111079. PubMed ID: 33378976
[TBL] [Abstract][Full Text] [Related]
16. KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges.
Passiglia F; Malapelle U; Del Re M; Righi L; Pagni F; Furlan D; Danesi R; Troncone G; Novello S
Eur J Cancer; 2020 Sep; 137():57-68. PubMed ID: 32745965
[TBL] [Abstract][Full Text] [Related]
17. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
18. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
Shepherd FA
J Clin Oncol; 2011 Nov; 29(31):4068-70. PubMed ID: 21969515
[No Abstract] [Full Text] [Related]
[Next] [New Search]
